Dr. Paul Oberstein discusses RASolute 302, a pancreatic cancer trial, and what a potential KRAS inhibitor breakthrough could mean for patients.
Dr. Paul Oberstein
Advertisement
Articles by Dr. Paul Oberstein
Dr. Paul Oberstein discusses how personalized mRNA vaccines may improve long-term survival for patients with pancreatic cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CURE
1
Breast Cancer Treatments Awaiting FDA Decisions: 4 to Watch
2
FDA Approves Etcamah Plus CDK4/6 Inhibitor for ESR1-Mutated Breast Cancer
3
How AI Is Changing Breast Cancer Screening
4
Prostate Cancer Treatments in the FDA Pipeline: What Could Come Next
5